LAG3 and melanoma: A phase I/IIa study (NCT01968109) evaluating efficacy and safety of the combination therapy with the anti-LAG-3 antibody BMS-986016 (relatlimab) and nivolumab in patients with melanoma that progressed during or after anti-PD-1/PD-L1 immunotherapy has reported a safety profile similar to that of nivolumab alone, but with superior efficacy.